SMXXF News Alert Summit Corporation (SMXXF) 2.3000 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Summit Corporation (SMXXF) 2.3000 $SMXXF

Plague - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgdb3j/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Takeda Pharmaceutical - Summit Corporation - Mucosis - iBio - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/xg...e_pipeline

Dementia Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pmw68m/dementia) has announced the addition of the "Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Sylentis S.A. - FORUM Pharmaceuticals Inc. - Ildong Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - WhanIn Pharmaceutical Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Summit Corporation plc - Oryzon Genomics S.A. - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - Tautatis Incorporated - Pacific Northwest Biotechnology, LLC - Otsuka Holdings Co., Ltd. - Chase Pharmaceuticals Corporation - Echo Pharmaceuticals B.V. - Chronos Therapeutics Limited - Alector LLC - ImStar Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/pmw68m/dementia

USHCC Announces 2014 Legislative Summit Featured Speakers
GlobeNewswire - Mon Mar 24, 9:07PM CDT
The United States Hispanic Chamber of Commerce (USHCC) is proud to announce the participation of an all-star lineup during its 2014 Legislative Summit, which will take place at the Capital Hilton from March 25 - 27. The Legislative Summit is the USHCC's premier advocacy event where the Hispanic business community hears from national political leaders, have access to high-level networking opportunities, engage in policy workshops, participate in procurement matchmaking sessions with federal agencies, and have the chance to meet with Congressional representatives on Capitol Hill.

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tuberculosis - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Tuberculosis
M2 - Mon Sep 02, 11:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bnt58v/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Tuberculosis. - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AVI BioPharma Inc. - Achillion Pharmaceuticals, Inc. - Advinus Therapeutics Pvt. Ltd. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BT PHARMA - Canopus BioPharma Incorporated - Chimerix, Inc. - Crucell N.V. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline Inc. - GlaxoSmithKline plc - Hollis-Eden Pharmaceuticals, Inc. - ISA Pharmaceuticals B.V. - Immune Network Research Ltd. - ImmunoBiology Limited - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Lipotek Pty Ltd - Medisyn Technologies, Inc. - MicuRx Pharmaceuticals, Inc. - Mondobiotech Holding AG - NeED Pharma s.r.l. - Okairos - Pharminox Limited - Piramal Healthcare Limited - Pt. Bio Farma - Recipharm AB - Sanofi-Aventis - Sequella, Inc. - Snowdon Inc. - Statens Serum Institut - Summit Corporation plc - TVAX Biomedical, LLC - Transgene SA - Vakzine Projekt Management GmbH - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/bn...berculosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Ebola Viral Infections - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g94m3t/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola Viral Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola Viral Infections. Scope - A snapshot of the global therapeutic scenario for Ebola Viral Infections. - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola Viral Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Tekmira Pharmaceuticals Corp. Medicago Inc. CombinatoRx, Incorporated Summit Corporation plc Functional Genetics, Inc. Evolva SA Vaxart, Inc. Prosetta Corporation For more information visit http://www.researchandmarkets.com/research/g9...bola_viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Metastatic Melanoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mttj8/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H2 2012" report to their offering. This data provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Metastatic Melanoma - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of products based on various stages of development ranging from discovery till registration stages - A feature on pipeline projects on the basis of monotherapy and combined therapeutics - Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type - Key discontinued pipeline projects - Latest news and deals relating to the products Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Metastatic Melanoma Overview Therapeutics Development An Overview of Pipeline Products for Metastatic Melanoma Companies Involved in Metastatic Melanoma Therapeutics Development Metastatic Melanoma - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - 3SBio Inc - AVAX Technologies - Abbott Laboratories - Antigenics - BioAlliance Pharma - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics - Eli Lilly and Company - F. Hoffmann-La Roche - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Incyte Corporation - Lorus Therapeutics - Millennium Pharmaceuticals - Molecular Insight Pharmaceuticals - Morphotek - Northwest Biotherapeutics - Novartis AG - Oncolytics Biotech - Ono Pharmaceutical - Osta Biotechnologies - Oxford BioMedica - Pain Therapeutics - Progen Pharmaceuticals Limited - Provectus Pharmaceuticals - Summit Corporation - Vical Incorporated - Viralytics For more information visit http://www.researchandmarkets.com/research/5mttj8/metastatic

Skin Inflammation - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cclx3v/skin_inflammation) has announced the addition of the "Skin Inflammation - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Skin Inflammation Overview Therapeutics Development An Overview of Pipeline Products for Skin Inflammation Companies Involved in Skin Inflammation Therapeutics Development Skin Inflammation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Skin Inflammation Therapeutics - Drug Profile Updates Skin Inflammation Therapeutics - Discontinued Products Skin Inflammation Therapeutics - Dormant Products Skin Inflammation - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned - APEIRON Biologics AG - Action Pharma A/S - Almirall, S.A - Amgen Inc - AnGes MG, Inc - AnaMar Medical AB - Anacor Pharmaceuticals, Inc - Array BioPharma Inc - Asubio Pharmaceuticals, Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - CREABILIS Therapeutics S.r.l. - Celtic Pharmaceutical Holdings L.P - Clarassance, Inc - Companies Involved in Skin Inflammation Therapeutics Development - Cutanea Life Sciences - Daiichi Sankyo Company, Ltd - Deciphera Pharmaceuticals, LLC - EMS S.A - Eisai Co., Ltd - Fougera - Galderma S.A. - GlaxoSmithKline plc - Hanall Pharmaceutical Co., Ltd - Hawthorn Pharmaceuticals, Inc - Hygeia Therapeutics, Inc - IMMD Inc. - JADO Technologies GmbH. - LEO Pharma A/S - MIKA Pharma GmbH - Maruho Co.,Ltd - MedImmune LLC - Melior Discovery, Inc. - Morphotek, Inc - Morria Biopharmaceuticals Plc - NKT Therapeutics, Inc - NicOx SA - Nippon Shinyaku Co., Ltd - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Palau Pharma S.A - Paloma Pharmaceuticals, Inc - Pharis Biotec GmbH - Phytopharm Plc - ProMetic Life Sciences Inc - Provectus Pharmaceuticals, Inc - Proximagen Neuroscience plc - R-Tech Ueno, Ltd - Regeneron Pharmaceuticals, Inc - Respiratorius AB - SARcode Corporation - SWITCH Biotech LLC - Stiefel Laboratories, Inc - Summit Corporation plc - Syntrix Biosystems, Inc - Viromed Co., Ltd - Welichem Biotech Inc For more information visit http://www.researchandmarkets.com/research/cc...flammation

Dermatitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrd9dn/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dermatitis. - A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Dermatitis Overview Therapeutics Development An Overview of Pipeline Products for Dermatitis Dermatitis Therapeutics under Development by Companies Dermatitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Dermatitis Therapeutics - Products under Development by Companies Dermatitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Dermatitis Therapeutics Development Drug Profiles Dermatitis Therapeutics - Drug Profile Updates Dermatitis Therapeutics - Discontinued Products Dermatitis Therapeutics - Dormant Products Dermatitis - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: (58) Including: - Almirall, S.A - Amgen Inc - AnGes MG - Array BioPharma Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eisai Co - Galderma S.A - GlaxoSmithKline - Hanall Pharmaceutical Co - LEO Pharma A/S - MedImmune LLC - NicOx SA - Nippon Shinyaku Co - Novartis AG - Nuvo Research Inc - Phytopharm - ProMetic Life Sciences Inc - Provectus Pharmaceuticals - Proximagen Neuroscience - R-Tech Ueno - Regeneron Pharmaceuticals, Inc - Stiefel Laboratories - Summit Corporation For more information visit http://www.researchandmarkets.com/research/hrd9dn/dermatitis

Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development




Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 13

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 53

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 28

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 19

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 35

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading

Top 5 Most Recently Viewed Articles

Securities Fraud Investigation Casts Shadow on Driven Brands

Updated Category News Views 331

The Unfolding Drama Surrounding Driven Brands Out of nowhere, the waters are getting choppy for Driven Brands Holdings, and it’s not just a casual dip; more like a tsunami warning. Ademi LLP is cranking up the heat with an investigation into possible securities fraud that’s got investors scratching their heads and probably running for cover. What’s the Big Deal?...

Continue Reading
Info-Tech Research Group Expands Focus in Asia-Pacific Markets

Updated Category News Views 292

Info-Tech Research Group Expands Its Global Footprint Info-Tech Research Group has recently expanded its global presence by launching a new office in Singapore while significantly ramping up investments in New Zealand. This strategic move enables the firm to provide more localized, outcome-driven support to IT leaders throughout Southeast Asia and the Australia-New...

Continue Reading
Laramide Resources' Strategic Exploration Plans in Kazakhstan

Updated Category News Views 144

Exploration Drilling Plans by Laramide Resources Laramide Resources Ltd., a leading organization in uranium exploration, has identified multiple promising targets within its Chu-Sarysu Project. This initiative is set to take place in a mineral-rich area renowned for its potential to yield significant deposits of uranium and other valuable minerals like rare earth elements...

Continue Reading
Stravito Unveils AI Personas for Accelerated Market Insights

Updated Category News Views 311

Stravito Introduces AI Personas for Enhanced Market Positioning Stravito supports brands in rapidly validating their ideas using advanced AI technology. In a dynamic market environment, Stravito has launched an initiative designed to drastically improve the speed and reliability of idea testing for brands. This revolutionary tool, known as Stravito AI Personas, transforms...

Continue Reading
Duni Introduces Innovative Take-Away Series Boosting Sustainability

Updated Category News Views 245

Duni Introduces Innovative Take-Away Series Boosting Sustainability Duni is excited to unveil a fresh series of take-away packaging that represents a significant leap towards sustainability. The company has developed new packaging solutions that feature a grey plastic base, which can significantly enhance recycling efforts compared to traditional black plastic. This move...

Continue Reading